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Objective: Obesity prevalence is increas-
ing worldwide and it is nowadays con-
sidered a real public health problem. Obesity is associat-
ed with co-morbidities like cardiovascular diseases (CVD)
and type 2 diabetes mellitus (T2DM), furthermore viscer-
al obesity can be related to low testosterone (T) plasma
levels. The link between obesity and hypogonadism (HG)
is complex and not completely clarified. Current guide-
lines suggest that screening for HG should be done in
subjects with obesity and T2DM. The aim of this evalua-
tion is to assess the estimated actual and future preva-
lence of obesity and related co-morbidities, in particular
HG, in the Italian general population. 
Materials and Methods: The Strategyst Consulting Inc.
recently completed an epidemiology forecast model for
several countries, looking at HG and CV/Metabolic
Disease, based on National Health and Nutrition
Examination Survey (NHANES) data collected between
1999-2010. Data from NHANES survey were used to eval-
uate the Italian  estimated prevalence of obesity and HG.
Results: Results show that obesity estimated prevalence
will increase in 2030 also in Italy. In addition, also the
prevalence of obese CVD and T2DM subjects will
increase too. Even Italian HG prevalence is estimated to
increase in the next two decades, irrespective of T thresh-
old considered (< 8, 10 and 12 nmol/L). In obese CVD
subjects the relative risk (RR) of developing HG (T < 8
nmol/L) is four times greater than in not-CVD obese sub-
jects (RR = 4.1, 3.1 and 1.9 accordingly to the aforemen-
tioned T thresholds for defining HG). Accordingly, the
estimated percentage of hypogonadal obese CVD and
T2DM subjects will rise in 2030.
Conclusions: The Strategyst epidemiology forecast model
has allowed to assess the current and future prevalence 
of obesity and its relative co-morbidities like HG in Italy.
Data emerged from this evaluation suggest that obesity
and HG prevalence will increase in Italian population 
and confirm the complex link between adipose tissue 
and male T levels. 
KEY WORDS: Visceral obesity; Hypogonadism; Future preva-
lence; Epidemiological forecast model.
Submitted 19 December 2013;  Accepted 28 February 2014
Summary INTRODUCTION
Obesity is an excessive accumulation of body fat mass
relative to lean body mass, usually due to unbalanced
diet and sedentary lifestyle (1). According to the World
Health Organization (WHO) the diagnosis of obesity is
often based on body mass index (BMI), calculated as
weight in kilograms divided by height in meters squared
(kg/m2). Individuals with BMI higher than 30 kg/m2 are
considered obese. Obesity is categorized in grade 1, if
BMI is of 30 to less than 35; grade 2, if BMI of 35 to less
than 40 and grade 3, if BMI is of 40 kg/m2 or greater (2).
Obesity is the greatest public health problem in the
world: several studies reported an association between
obesity and increasing risk of developing CVD, cancer
and common chronic disease, such as T2DM and hyper-
tension, all diseases that can lead to a reduced quality of
life and premature death (3). Moreover, visceral obesity
has been associated with alteration in sex steroid hor-
mone concentrations like HG, especially in adult males
(4-7). The Organization for Economic Co-operation and
Development (OECD) projections suggest that more than
2 in 3 people will be overweight or obese in some of the
OECD countries by 2020 (http://www.oecd.org/els/health-
systems/obesityandtheeconomicsofpreventionfitnotfat.htm). 
Indeed, we are facing with a real global epidemic that is
spreading in many countries and it can cause, in the
absence of immediate action, very serious health prob-
lems in the coming years (1). The Strategyst Consulting
Inc. recently completed an epidemiology forecast model
for several countries, looking at HG and CV/Metabolic
Disease, based on NHANES data collected between
1999-2010. Data from NHANES were used to show the
degree of overlap between disease states and then to
modify the raw prevalence values in NHANES in order
to match the local prevalence in the particular coun-
tries, such as Italy. The aim of this evaluation is to assess
the current and future prevalence of obesity and its rela-
tive comorbidities, mostly HG, in Italy.
MATERIAL AND METHODS
NHANES is a cross-sectional study designed to assess the
health and nutritional status of adults and children in the
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United States. In this survey every subject underwent an
interview and an extensive physical examination. In some
cases a morning blood sample was collected for bio-
chemical and hormonal analyses, such as T in male (9). 
Informations on age and race/ethnicity were self-reported.
During physical examination, height and weight, as well as
waist and hip circumferences were measured and BMI was
calculated as weight in kilograms divided by the square of
height in meters. Participants were defined as having dia-
betes if they answered “yes” to the question, “Have you ever
been told by a doctor or other health professional you had dia-
betes or sugar diabetes?” and as having CVD if they answered
yes to the question, “Have you ever been told by a doctor you
had heart attack, an angina pectoris or a coronary heart dis-
ease?” (9). Detailed information regarding the collection of
data in NHANES is available elsewhere (NHANES III data
files, documentation, and codebooks. Available online
from http://www.cdc.gov/nchs/ nhanes/about_nhanes.htm). 
The Strategyst Consulting Inc recently completed an epi-
demiology forecast model for several countries, looking
at Hypogonadism and Cardiovascular/Metabolic Disease,
based on National Health and Nutrition Examination
Survey (NHANES) data collected between 1999-2010.
Data from NHANES were analyzed for understanding
the general CV/metabolic patient population, as well as
the distribution of T levels within the pool, knowing that
this differs by age and BMI, and possibly also by CV sta-
tus. From this data the percentages of relative risk of
developing CVD and T2DM were calculated in the U.S.
population and then applied for other countries, includ-
ing Italy, on the basis of WHO data. WHO had previ-
ously performed several forecasting evaluation on CV
and metabolic health across the world. 
This allowed Strategyst Consulting Inc. to make projections
for each country of the CV and metabolic diseases from
2013 to 2030. T levels are pretty consistent across the
globe, with variations between countries being due to
varying demographic profiles and levels of obesity and CV
risk factors. For this reason, only NHANES testosterone
data were used, as they were the only source that allowed
to create HG populations with respect to all the risk fac-
tors (and their mutual comorbidities), and embody the
very complex set of Odds Ratios that describe these pop-
ulations. Hence, data from NHANES were used to show
the degree of overlap between disease states, then to mod-
ify the raw prevalence values in NHANES to match the
local prevalence in the particular country analyzed.
RESULTS AND DISCUSSION
Prevalence and trends of obesity in Italian adults
In the last thirty years, the worldwide prevalence of obesi-
ty has almost doubled, not with homogeneously distribu-
tion (11). United States is one of the countries that experi-
enced the largest absolute increase in the number of over-
weight and obese people between 1980 and 2008 (11).
About 35% of U.S adults were obese in 2011-2012, with a
higher percentage of middle-aged obese adults aged 40-59
than younger adults aged 20-39 or older adults aged 60
Figure 1.
Panel A.
Male obesity prevalence from
2013 to 2030 in Italy.
Panel B-C.
Percentage of obesity as a
function of age bands in Italy,
actually (Panel B) 
and in 2030 (Panel C).
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and over (12). According to data released in 2008 by the
OECD, in Italy about 1 person in 10 was obese
(http://www.oecd.org/els/health-systems/obesityandtheeconom-
icsofpreventionfitnotfat-italykeyfacts.htm). 
Figure 1 shows the trend of obesity (BMI ≥ 30 kg/m2)
prevalence in Italy from 2013 to 2030, in the adult male
population (18-over 65 years old). At present, according to
Strategyst estimated data, 13.8% of Italian men is obese.
This prevalence is similar to that referred by PASSI
(Progressi delle Aziende Sanitarie per la Salute in Italia), a
monitoring system of Italian population (http://www.epicen-
tro.iss.it/problemi/obesita/epid.asp). Obesity prevalence will
increase in the coming years and, on the basis of our esti-
mated data, it will reach 16.8% in 2030 (Figure 1,
Panel A). 
Nowadays, among Italian adult obese subjects, there is a
higher percentage of patients aged 60-64 (17.9%) than
aged 40-59 (15.7%) or aged 65 and over (12.5%) (Figu -
re 1, Panel B). In the next future, the percentage of obesity
is estimated to rise in each age group, but mostly in mid-
dle aged adults, reaching 22.6% among 40-59 years old
men and 21.7% among 60-64 years old men, similarly to
US male population (Figure 1, Panel C).
Prevalence and trends of CVD and T2DM in Italian adults
The INTERHEART study group identified the abdominal
(visceral) obesity as one of the nine major risk factors for
myocardial infarction (including smoking, lipids, hyper-
tension, T2DM, diet, physical activity, alcohol consump-
tion, and psychosocial factors), accounting for more than
90% of the worldwide risk (15). These risk factors were
shared by men and women, almost in every geographic
region and every racial/ethnic group. It is well known that
visceral obesity, versus subcutaneous fat, is characterized
by a hypersecretion of pro-atherogenic, pro-inflammatory
and pro-diabetic adipo-cytokines, and by an enhanced free
fatty acid turnover and toxicity (16), an increased basal
sympathetic tone, a hypercoagulable state and a chronic
low-grade systemic inflammation (17). This causes the
development of insulin resistance (IR) and the increased
risk of CVD as ischemic heart diseases (angina and myocar-
dial infarction, MI) and congestive heart failure (CHF). In
addition, visceral obesity can be considered a “conditional”
risk for developing T2DM, dyslipidaemia and hyperten-
sion, all independent CV risk factors (17).  Figure 2, Panel
A shows that the prevalence of T2DM, angina, history of
MI and CHF is expected to grow highly in the coming
A.
B.
Figure 2.
Panel A.
Male prevalence of
different  co-morbidities
from 2013 to 2030 
in Italy [History of
Myocardial Infarction
(MI), Angina,
Congestive Heart
Failure (CHF) 
and type 2 Diabetes
Mellitus (T2DM)].
Panel B.
Male prevalence of
different co-morbidities
as a function of
different age bands 
in Italy (History of MI,
Angina, CHF 
and T2DM).
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years. At the moment, the estimated Italian proportion of
men with a history of MI is 4.8%, of angina 5.4%, of CHF
2.7% and of T2DM 9.8% reaching 7.4%, 8.2%, 4.2% and
14.4%, respectively, in 2030. Hence, the prevalence of CV
and metabolic diseases will be almost doubled within 17
years in Italy. Concerning the prevalence of angina, history
of MI, CHF and T2DM as a function of age, it rapidly
increases for all these diseases with aging, especially after
40 years old. In particular, for T2DM reaches a prevalence
of 21% in 70 years old men (Figure 2, Panel B). In 2013,
among the estimated obese sample, 26% has co-morbidi-
ties like T2DM and CVD (12% and 14%, respectively),
whereas 74% has not (Figure 3, Panel A). Normal weight
subjects have lower rates of CVD (13%) and T2DM (10%),
respectively (data not shown). 
This is consistent with a higher prevalence of CV and
metabolic diseases in obese subjects. It is estimated that
the prevalence of “unhealthy” obese (with CVD and
T2DM) will rise reaching 32% in 2030 (16% T2DM and
16% CVD) whereas “healthy” obese (without CV and
metabolic morbidity) will decrease to 68% (Figure 3,
Panel B). Overall these data show that prevalence of obe-
sity in Italy will increase, in particular the percentage of
obese male subjects with co-morbidities. 
Prevalence and trends of hypogonadism in Italian adults
Normal aging is characterized by a slight decline of T lev-
els (18). Considering changes in T levels by age, there is
not a consensus for  definition of HG (19). For example,
the American Association of Clinical Endocrinologists (20)
and the Endocrine Society (21) proposed different T cut-
offs for diagnosing HG, i.e. 7 nmol/L (200 ng/dl) and
10.4 nmol/L (300 ng/dl) respectively. 
According to a consensus among different scientific
Andrology Societies (18, 19, 22) men with T levels below
8 nmol/L (231 ng/dl) should receive T replacement thera-
py, whereas those with T levels above 12 nmol/L (346
ng/dl) should not be treated. Moreover, it was introduced
the concept of the so-called “late-onset hypogonadism”
(LOH): a clinical and biochemical condition of the
advancing age, characterized by peculiar symptoms and
by low levels of serum T, i.e. total T below 12 nmol/L. (21-
23). Recently, Wu et al. (24) proposed a T cut off 11
nmol/L (230 ng/dl) and free T levels of less than 220
pmol/L (< 64 pg/ml) for diagnosing LOH, in the presence
of at least three sexual symptoms (low libido and reduced
spontaneous and sex-related erections).
Therefore, the estimated number of hypogonadal men is
different, depending on the T cut off used and on age
(18). In Italy, by Strategyst model evaluation, the present
estimated prevalence of HG is 7, 12.5 and 22% consid-
ering T < 8, 10 e 12 nmol/L, respectively. It is expected
that, in 2030, this prevalence will rise reaching 8.1, 14.7
and 24.2%, respectively (Figure 4, Panel A). 
In observational studies involving male general popula-
tion, the prevalence of HG is increasing as a function of
age, although at a different rate, as observed in US (25-
27) and European male population (24). Accordingly,
analyzing Strategyst Italian forecast, HG prevalence
increases by age irrespective of T threshold considered,
with the highest rate in older subjects (> 65 years old)
reaching 7, 12.5, 22%, for T levels < 8, 10, 12 nmol/L,
respectively (Figure 4, Panel B). 
Obesity and hypogonadism
Several studies have demonstrated an inverse relationship
Figure 3.
Panel A-B.
Estimated distribution of
obese male sample in
2013 and 2030; 
Panel A and Panel B,
respectively.
Panel C-D. 
Estimated distribution of
hypogonadal obese male
sample in 2013 and 2030;
Panel C and Panel D,
respectively.
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between BMI and waist circumference, indicators of vis-
ceral obesity, and T levels over all age groups (28-30). An
increase in BMI from normal weight to obese range may
be equivalent to a 15 years fall in T levels (23). In the
Massachusetts Male Aging Study (MMAS) authors demon-
strated that a healthy lifestyle, a normal body weight and
the absence of chronic disease were more important deter-
minants of androgen levels than ageing (25-26). The link
between obesity and HG is complex and not completely
understood. Visceral obesity can probably be considered
an important cause of HG, but at the same time, HG could
be a cause of obesity and insulin resistance, consequently
establishing a vicious cycle (31-35). 
Figure 5, Panel A shows that the estimated percentage of
obese males in Italy is higher in HG sample than in gen-
eral population. There are some considerable evidences
on the role of T in regulating body composition. It
seems that T concurs in increasing and maintaining
muscle mass and reducing fat mass (36). 
This suggests a possible role of T deficiency in the etiol-
ogy of obesity so that HG might be considered an addi-
tional component of Metabolic Syndrome (MetS) in males
(37). In fact, in men undergoing androgen ablation ther-
apy for advanced prostate cancer it was observed a sig-
nificant increase in total body fat mass and reduction in
lean body mass (38). 
Criteria for MetS were present in more than 50% of these
men, predisposing them to higher CV risk (39). The rela-
tionship between reduced T levels and CVD still repre-
sents a matter of speculation. Cross-sectional epidemio-
logical studies clearly show a significant association
between HG and CVD (40-41). In a recent meta-analysis
Araujo et al. demonstrated that HG was associated with an
increased risk of all causes and CVD mortality (42). 
Figure 5, Panel B shows the estimated Italian prevalence of
HG (as different T threshold considered: 8, 10, 12 nmol/L)
in obese subjects with or without previous CVD. In obese
CVD subjects the relative risk (RR) of developing HG
(T < 8 nmol/L) is four times greater than in not-CVD obese
subjects (RR = 4.1, 3.1 and 1.9 accordingly to T cut off of
8, 10 e 12 nmol/L). 
This is a cross-sectional analyses, therefore we cannot
establish a relationship of causality, however this suggests
that the presence of previous CVD predispose obese sub-
jects to develop HG and this risk is higher for lower T
plasma levels. A large body of evidence supports the
association between low T, T2DM and MetS (31-35).
According to data shown in Figure 5B, in Italy the esti-
mated percentage of hypogonadal obese male subjects
with T2DM and CVD is 19 and 16%, respectively
(Figure 3, Panel C), higher than in subjects with only
obesity (Figure 3, Panel A). 
Figure 4.
Panel A.
Estimated Italian
hyponadism (HG)
prevalence from 2013 
to 2030, considering 
different testosterone (T) 
cut off.
Panel B.
Prevalence of
hyponadism (HG) 
as a function of 
age bands, considering 
different testosterone 
cut off, in Italy.
A.
B.
Pr
ev
al
en
ce
 o
f 
H
G
 (
%
)
Pr
ev
al
en
ce
 o
f 
H
G
 (
%
)
Age bands
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
18-29 30-39 40-49 60-64 > 65
Below 12 nmlol/L
Below 10 nmol/L
Below 8 nmol/L
% Below 8
% Below 10
% Below 12
30%
28%
26%
24%
22%
20%
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
25%
20%
15%
10%
5%
0%
Boddi new_Stesura Seveso  26/03/14  10:18  Pagina 30
31Archivio Italiano di Urologia e Andrologia 2014; 86, 1
Obesity and hypogonadism in Italy
Hence, the presence of HG confers a higher probability
of developing CVD and T2DM. Furthermore, the esti-
mated percentage of obese hypogonadal subjects with
CVD and T2DM will rise in 2030, reaching 26 and 20%
respectively (Figure 3, Panel D). 
This is consistent with previously shown data. Current
guidelines suggest that screening for HG should be done
in subjects with obesity, T2DM and MetS (18, 19, 21).
CONCLUSION
Obesity prevalence is increasing worldwide and this phe-
nomenon involves Italy too. At this moment, 13.8% men
are obese and they will became 16.8% in 2030. The
increase of prevalence will be greater in middle aged
adult male. In coming years also the prevalence of
T2DM, angina, CHF and history of MI will rise. Italian
obese subjects have a higher rate of T2DM and CVD and
this rate is estimated to rise. 
Obesity is also related to HG. The estimated prevalence
of HG in Italy differs according to different cut offs pro-
posed by Scientific Society, from 2 to 22% and will
increase until 8-24% in 2030. Concerning the data
shown in this evaluation, the estimated prevalence of HG
increases as a function of age and hypogonadal subjects
are more often obese than general population. 
Conversely, obese subjects have a higher risk of devel-
oping HG, in particular if they have suffered from CVD.
Finally, obese-hypogonadal males have a higher rate of
T2DM and CVD than eugonadal obese male.
The Strategyst epidemiology forecast model allowed to
assess the current and future prevalence of obesity and
its relative comorbidities like HG in Italy. A limitation of
the present report should be recognized: prevalence esti-
mations for Italy are based on epidemiological values of
US male population which could be different from the
Italian one. 
However, data emerged from this evaluation suggests
that obesity and HG prevalence will increase in the
Italian population and confirm the complex link
between adipose tissue and male T levels.
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